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Key Points
• RUNX1 mutations lead
to a block in granulo-
cytic differentiation that
can be partially rescued
by CEBPA
overexpression.
• RUNX1 mutations
deregulate gene
expression on
specific loci.
To unravel molecular mechanisms by which Runt-related transcription factor 1 (RUNX1)
mutations contribute to leukemic transformation, we introduced the RUNX1-S291fs300X
mutation in human CD341 stem/progenitor cells and in human induced pluripotent stem
cells (iPSCs). In both models, RUNX1mut overexpression strongly impaired myeloid
commitment. Instead, self-renewal was enhanced, as shown, by increased long-term
culture-initiating cell frequencies and enhanced colony-forming cell replating capacity.
Long-term suspension cultures with RUNX1mut-transduced cord blood (CB) CD341 cells
continued for more than 100 days, during which the cells displayed an immature
granulocyte-macrophage progenitor-like CD341/CD1231/CD45RA1 phenotype. The CD341/CD382
hematopoietic stem cell (HSC) populationmost likely acted as cell of origin, as HSCs provided
the best long-term proliferative potential on overexpression of RUNX1mut. CEBPA
expression was reduced in RUNX1mut cells, and reexpression of CEBPA partly restored
differentiation. RNA-seq analysis on CB/iPSC systems and on primary patient samples
confirmed that RUNX1mutations induce amyeloid differentiation block, and that a common
set of RUNX1mut-upregulated target genes was strongly enriched for gene ontology terms
associated with nucleosome assembly and chromatin structure. Interestingly, in compar-
ison with AML1-ETO binding in acute myeloid leukemias (AMLs), we found significantly
distinct genomic distribution and differential expression for RUNX1mut of genes such as TCF4,
MEIS1, and HMGA2 that may potentially contribute to the underlying difference in clinical
outcomes between RUNX1mut and AML1-ETO patients. In conclusion, RUNX1mut appears to
induce a specific transcriptional program that contributes to leukemic transformation.
Introduction
Aberrations in the functionality of transcription factor Runt-related transcription factor 1 (RUNX1) are
linked to myeloid malignancies. Mutations in the RUNX1 gene (RUNX1mut) have been identified in
myelodysplasia1-4 and de novo and secondary acute myeloid leukemia (AML),5 and are generally
associated with unfavorable clinical outcomes.6 Familial RUNX1 mutations are associated with
familial thrombocytopenia, and patients have a predisposition to AML development.7,8 In addition to
the point mutations in the RUNX1 gene, a number of fusion partners of RUNX1 and their
deregulating functions have been described in detail, including AML1-ETO,9 whereas mutations in
RUNX1 have hardly been studied.
RUNX1 is essential during multiple stages in the hematopoietic development, including the formation of
definitive HSCs,5,10 B-cell maturation,11 megakaryocyte maturation, and granulocytic differentiation.12 RUNX1
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mutations, both heterozygous and homozygous, are located along
the full length of the protein. This usually results in single amino-
acid substitutions in the DNA-binding domain or in C-terminal
truncation mutations lacking all or part of the activation
domain.13-16 Loss-of-function studies in mice have demon-
strated that RUNX1 deficiency is associated with an expansion
of the common myeloid progenitors and granulocyte-macrophage
progenitor (GMP) pool, which could be rescued by inactivation of
Hmga2.17 In addition, RUNX1 loss leads to an increased suscep-
tibility to AML development in collaboration with MLL-ENL and
N-Ras, suggesting that RUNX1 has a tumor-suppressor function.18,19
However, recent work has illustrated the importance of RUNX1wt
expression in AML1-ETO and MLL-AF9 cells, suggesting a
prosurvival function in leukemogenesis.20
Here, we studied the in vitro growth and the RUNX1 binding
pattern and expression profile induced by the C-terminal-
truncating RUNX1-S291fs300X mutant in cord blood (CB)
CD341 cells and induced pluripotent stem cells (iPSCs). We
then compared these findings with those from primary RUNX1mut
AMLs. The results indicate that a single RUNX1 mutation leads to
increased self-renewal, enhanced long-term culture-initiating cell
(LTC-IC) frequency, and long-term maintenance of CD341 cells.
Chromatin immunoprecipitation (ChIP)-seq and RNA-seq experi-
ments, including primary AML samples, indicate that RUNX1
mutations, independent of the model, induce a unique transcrip-
tional program. By comparing the effects of RUNX1mut with the
programs triggered by AML1-ETO, we found that RUNX1mut
targets several other genes that possibly affect the clinical
outcomes of these 2 types of leukemia.
Materials and methods
Human cells
Umbilical CB was derived after healthy full-term pregnancies from
the obstetrics departments of the Martini Hospital and the University
Medical Centre in Groningen, The Netherlands. Normal bone marrow
cells were derived from healthy volunteers or extracted from healthy
hipbone after hip replacement surgery, after informed consent.
Peripheral blood stem cells were extracted after stem cell mobi-
lization from patients, after informed consent. AML blasts from
peripheral blood or bone marrow from patients with de novo AML
were studied after informed consent was obtained, in accor-
dance with the Declaration of Helsinki. The protocol was
approved by the Ethical Review Board of the University Medical
Center Groningen, Groningen, The Netherlands. To obtain
relative pure cell populations and the largest fraction of leukemic
cells, fluorescence-activated cell sorting (FACS) based on
expression of cell surface marker CD33 or CD34 was performed.
An overview of all mutations can be found in supplemental
Table 2, and more information about these AMLs is described in
Yi et al.21 The megakaryoblast-derived iPSCs were obtained from
Sanquin Amsterdam.22 Full culture methods and differentiation of
RUNX1mut iPSCs toward the granulocytic lineage are described
in the supplemental Methods.
Flow cytometry
Surface marker analysis was performed on the LSR-II (BD
Biosciences). A list of antibodies can be found in the supple-
mental Methods.
Immunoblotting
Whole-cell extracts were prepared by boiling an appropriate
number of cells in Laemmli sample buffer for 5 minutes with
subsequent separation on 10% sodium dodecyl sulfate-acrylamide
gels. Proteins were transferred to PVDF (Millipore), using wet
transfer. RUNX1 was detected with a-RUNX1 antibody (Abcam
23980) 1:2000 and b-actin (Abcam 16039).
CEBPA rescue experiments
Weeks 8 to 10, CB RUNX1mut cells were transduced with
retroviral vector containing CEPBA fused to the estrogen receptor
domain (described previously23). Transduced cells were sorted and
plated in growth mediumwith and without 100 nM 4-hydroxytamoxifen.
After 3 days, expression of cell surface markers and RNA expression
was determined.
RNA extraction and cDNA synthesis
RNA was extracted from 13106 iPSC control and RUNX1mut
cells, using the RNeasy mini kit (Qiagen), including on-column
DNaseI treatment. Ribosomal RNA was depleted by using
the ribo-zero rRNA removal kit (Illumina). RNA was fragmented
in 300-bp fragments by incubation for 7.5 minutes in fragmentation
buffer (200 mM Tris-acetate, 500 mM potassium acetate, 150 mM
magnesium acetate at pH 8.2). First-strand cDNA synthesis was
performed using superscript III (Life Technologies), followed by
synthesis of the second cDNA strand.
Chromatin immunoprecipitation
Cells were crosslinked with 1% formaldehyde for 10 minutes at
room temperature at a concentration of 153106 cells/mL. The
fixed cells were sonicated for 5 minutes (30 seconds on, 30
seconds off), using the Diagenode Bioruptor. Sonicated chroma-
tin was centrifuged for 10 minutes at maximum speed and then
incubated with either 5 mg RUNX1 antibody (Abcam ab23980)
that recognizes both RUNX1wt and RUNX1mut proteins or
2 mg flag M2 antibody that recognizes the overexpressed
RUNX1mut protein (Sigma F3165). Beads were washed with 4
different wash buffers, and chromatin was eluted from the beads.
DNA proteins were de-crosslinked, and samples were purified
using the Qiaquick MinElute PCR purification kit. Library prepara-
tion, Illumina high-throughput sequencing, and ChIP-seq and
RNA-seq data analysis is described in detail in the supplemental
Materials.
Statistical analysis
A paired or unpaired 2-sided Student t test was used to calculate
statistical differences. P , .05 was considered statistically signif-
icant. Error bars represent standard deviation: *P, .05; **P, .01;
***P , .001.
Results
RUNX1mut cells display impaired erythroid
differentiation, but increased myeloid replating
capacity and expansion
CB CD341 cells were transduced with the RUNX1 mutant
S291fs300X (RUNX1mut; Figure 1A), and overexpression was
confirmed by quantitative reverse transcription polymerase chain
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reaction (qRT-PCR; supplemental Figure 1A). The progenitor
frequency was determined by colony-forming cell (CFC) assay.
A decline in erythroid burst-forming unit (BFU-E) formation
was observed without a difference in CFU-G or CFU-M colony
formation (Figure 1B). In addition to a reduction in BFU-E
numbers, the colony morphology reflected an immature appear-
ance (data not shown), which was linked to a reduced expression
of GATA1, an important regulator of erythroid differentia-
tion (supplemental Figure 1B). In addition, a strong reduction in
expansion was observed when CB CD341 RUNX1mut cells were
cultured under erythroid-permissive conditions (supplemental
Figure 1C). In contrast, the CFC replating capacity of myeloid
progenitors was enhanced on overexpression of RUNX1mut
(Figure 1B). This was especially the case in the more primitive
CD142/CD152 cell fraction compared with the more differenti-
ated CD141/CD151 fraction (Figure 1C-D).
To determine whether RUNX1mut-transduced cells could also
be propagated for a longer period in the context of a bone
marrow microenvironment, CB CD341 RUNX1mut cells were
cultured on MS5 bone marrow stroma (Figure 2A; supplemental
Figure 2A). No significant growth advantage was observed
for the RUNX1mut cells compared with control CB CD341
cells. However, RUNX1mut-transduced cells were maintained
under the stroma, without significant expansion, for up to 10 to
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Figure 1. RUNX1mut increases replating capacity. (A) Schematic overview of RUNX1wt and RUNX1 S291fs300X mutant. (B) CFC and replating potential of RUNX1mut
vs control. At the start, 500 cells were plated per dish in duplicates. Between days 10 to 14, the number of colonies were scored and all colonies were harvested. For each
replating, 25 000 cells per dish were plated. Replating potential of control vs RUNX1mut in the CD142/CD152 fraction (C) and replating potential of control vs RUNX1mut in
the CD141/CD151 fraction (D). At the start, 500 cells were plated per dish in duplicates. Between days 10 and 14, the number of colonies were scored and colonies were
harvested and stained for CD14 and CD15. In a new CFC, 25 000 CD141 or CD151 cells and 25 000 CD142/CD152 cells were FACS sorted. After 10 to 14 days, this was
repeated for another replating round. *P , .05; **P , .01.
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12 weeks. FACS analysis of these stroma-adherent RUNX1mut
cells after 10 weeks of culture revealed that a high proportion of
the cells, in contrast to the control cells (supplemental Figure 2B),
had a persistent immature phenotype, as shown by expression
of CD341/CD382 and high expression of CD123 and CD45RA
(Figure 2B).
In addition, long-term myeloid suspension cultures were initiated
to study the growth potential of CB CD341 RUNX1mut cells during
a longer periodwithout a bonemarrowmicroenvironment (Figure 2C).
Control transduced cells fully differentiated to macrophages after
8 weeks of culture, whereas the RUNX1mut CB cell culture had
a persistent population of more immature monoblastic cells that
expanded for more than 3 months (supplemental Figure 2C). Further
characterization of RUNX1mut cells by FACS analysis at week 10
identified a mixture of CD341 and CD342 cells (Figure 2D). CD342
cells were CD141/CD152 (supplemental Figure 2D), whereas
the CD341 cell population consisted of a CD381 and a large
CD382 subfraction, suggesting a HSC phenotype. The CD341
CD381 fraction strongly expressed both CD123 and CD45RA,
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Figure 2. RUNX1mut-transduced CB CD341 cells have
increased growth potential, LTC-IC-frequency, and CD341
maintenance. (A) Relative expansion in MS5 coculture of control vs
RUNX1mut. Growth curve of MS5 coculture (5 weeks). After 5 weeks,
the MS5 was replated (see supplemental Figure 2A for continued
growth). (B) Marker expression analysis of adherent fraction of
RUNX1mut cells in MS5 coculture after 10 weeks. Expansion of
suspension fraction was very limited and did not allow for surface
marker expression after 10 weeks. (C) Relative expansion in liquid
culture over a course of several weeks in control vs RUNX1mut (n 5 3).
(D) Marker expression analysis of RUNX1mut cells in liquid culture after
10 weeks. (E) CD341 expression of 3 CB control vs RUNX1mut cells in
time. Each line represents a different culture. (F) LTC-IC frequency of
control vs RUNX1mut cells. *P , .05.
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suggesting an accumulation at the GMP stage (Figure 2D). In
addition to these phenotypic markers, at week 10, RUNX1mut cells
also showed increased expression of several markers that have
been described on leukemic stem cells, such as CD116, IL1RAP,
and CD135 (supplemental Figure 2E).24We observed an initial loss
of the CD341, which reappeared after 6 to 7 weeks of culture
(Figure 2E). Based on the observed differentiation block and the
high percentage of CD382 in our MS5 coculture, we hypoth-
esized that RUNX1mut had induced distinct phenotypes in the
immature stem cell fraction (CD341CD382) relative to the
mature (CD341/CD381) progenitor cell fraction. To test this
hypothesis, CB cells were transduced with RUNX1mut and
sorted for CD341CD382 and CD341CD381 cells, and then
expanded in suspension cultures over time (supplemental
Figure 2F). The immature cell population with blast cell
morphology originated mostly in the CD341/CD382 fraction,
whereas the CD341/CD381 fraction had a higher amount of fully
differentiated macrophages (supplemental Figure 2G), suggesting
that the HSC population acts as the cell of origin. This is in line with
the findings of an increased stem cell frequency of CB CD341
RUNX1mut cells after 4 weeks of stromal cocultures (Figure 2F).
To exclude the possibility that the long-term expansion was limited
to fetal-CB-derived CD341 cells, adult bone marrow (n 5 2, not
shown) and adult peripheral blood (n 5 2) CD341 cells were
transduced with the RUNX1mut construct (supplemental
Figure 2H). In all the experiments, long-term expansion for 10
weeks was obtained and provided a similar phenotype. These
findings indicate that expression of the RUNX1mut impairs myeloid
and erythroid maturation, results in a differentiation block at
the GMP stage, and enhances CFC replating and stem cell
frequencies.
The RUNX1mut phenotype is characterized by low
CEBPA expression and can be partially rescued by
re-expression of CEBPA
We hypothesized that the differentiation block could be abolished
by culturing RUNX1mut cells in granulocytic differentiation medium
containing granulocyte colony-stimulating factor (G-CSF). Interest-
ingly, G-CSF did not induce granulocytic differentiation, in contrast
to control cells (supplemental Figure 3A). FACS analyses showed
that the RUNX1mut cells lost the expression of the G-CSF receptor
(CD114) over time (Figure 3A). We therefore analyzed the
expression levels of several known RUNX1 target genes important for
granulocytic differentiation, such as CEBPA and SPI1. This analysis
showed a 2-fold decline in CEBPA expression, a key regulator of
granulocytic differentiation (Figure 3B). With the publicly available
TCGA data set, we identified 16 AMLs with a RUNX1 mutation and
confirmed that a reduced expression of CEBPA is a common feature
of RUNX1mut-expressing cells, in comparison with RUNX1wt
(supplemental Table 1; Figure 3C).25 To determine whether
CEBPA downregulation was the main cause of the observed
GMP differentiation block, we overexpressed a CEBPA-ER
fusion construct in week 10 RUNX1mut CD341 cells. Stimulation
with 4OH-tamoxifen resulted in a decline in expansion, increased
expression of CD15 and CD14, and decreased expression of
CD34 (Figure 3D). Morphological studies revealed a rapid decline
in monoblastic-like cells after 3 days of culture (Figure 3E), but no
granulocytic cells were observed. qRT-PCR and FACS revealed
only a limited increase of CD114 mRNA levels and cell surface
expression (supplemental Figure 1A; supplemental Figure 3C),
whereasCTSG andMPO, 2 important genes involved in granulocytic
differentiation, were not altered, suggesting that CEBPA is
an important downstream target of RUNX1mut, but also that
other targets might be crucial in this deregulated granulocytic
differentiation.
RUNX1mut expression in differentiating iPSC model
results in a differentiation block of the myeloid
lineage by direct regulation of RUNX1mut
target genes
As a second method to model the effect of the RUNX1mut without
interference from additional mutations, we used iPSCs. In these
cells, expression of the RUNX1mut was induced during hemato-
poietic development in vitro (Figure 4A). The tetracycline-inducible
promoter enables effective RUNX1mut expression because of the
addition of doxycycline (supplemental Figure 4A-B). Expression of
the RUNX1mut was induced directly after mesoderm differentiation
(day 0) or at various stages during hematopoietic development
(days 6, 10, 14). Phenotyping the cells over time revealed a retained
expression of CD34 on RUNX1mut expression (Figure 4B;
supplemental Figure 4C) and a decreased number of differentiated
(CD151) cells in RUNX1mut-expressing cells compared with non-
induced cells (Figure 4C). Induction of RUNX1mut at early times (day
0) resulted in a short delaying effect on HSC formation, but otherwise
no abnormal differentiation was observed. In combination with the
monoblastic appearance of these cells (supplemental Figure 4D), this
suggests a block in differentiation, similar to that observed for the
CB data. These data were corroborated by RNA-seq analysis of
control vs dox-induced iPSCs, which revealed, similar as for the
CB model, reduced levels of CEBPA in the RUNX1mut-expressing
cells (Figure 4D).
Identification of a RUNX1mut-specific gene program
To determine the relevance of the RUNX1 target genes in primary
AML cells, we then compared transcriptional differences initiated by
RUNX1mut by RNA-seq in CB-RUNX1mut cells, iPSC-RUNX1mut
cells, normal bone marrow CD341 (GSE63569),26 monocytes,
macrophages, and granulocytes, as well as to patient AML cells
harboring RUNX1mut (supplemental Figure 5A). PCA analysis
based on expression revealed clustering of specific cell types
and CD341 cells: most of the undifferentiated cell populations,
including the iPSC and CB models, clustered on 1 side of the
PCA, and the differentiated cells on the opposite side (Figure 5A).
To map the compositional difference of RUNX1mut-expressing
cells systematically, we used the CIBERSORT deconvolution
method.27 This showed that a large proportion of the cell
population was carrying not only a CD341 progenitor signature
but also a substantial monocytic signature, whereas a granulo-
cytic signature was nearly absent (Figure 5B). We also found
that genes normally expressed in granulocytes showed de-
creased expression levels in RUNX1mut-expressing models and
primary AMLs, whereas the expression levels of monocytic-
related genes were comparable (Figure 5C; supplemental
Figure 5B-C). This indicates that RUNX1mut cells maintain a
progenitor phenotype featured by monocytic characteristics,
but only granulocytic genes were dramatically repressed by
aberrant RUNX1 protein, suggesting that RUNX1mut predom-
inantly affects granulocytic differentiation.
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Using k-means clustering, we visualized differentially expressed
genes between RUNX1mut-expressing cells and normal CD341
HSPCs (Figure 5D). This revealed 4 clusters, of which cluster
4 represents 556 genes that are downregulated in all RUNX1mut-
expressing groups compared with normal CD341 cells. This
cluster comprises enrichment for genes involved in inflammation
and immune response, suggesting an effect on myeloid cell
maturation (Figure 5E). Cluster 3 represents a set of 542 genes
commonly upregulated in all RUNX1mut-expressing cells, but not
in CD341 cells. This RUNX1mut-specific gene cluster is enriched
for genes related to chromatin organization, including several
small nucleolar RNAs, thus suggesting a role in RNA processing.
This transcriptome-wide exploration indicates that in vitro RUNX1mut
models can recapitulate the altered transcriptional landscape
induced by RUNX1mut in patient AML cells. Moreover, it
identified the RUNX1mut-specific program in the primary AMLs,
suggesting that the additional transcriptional alterations in these
AML cells (eg, in cluster 1 and 2) might be a result of other genetic
lesions.
Global RUNX1mut binding in CB and iPSC models
binding in primary AMLs with RUNX1 mutations
To define binding sites of RUNX1 and compare these within
our CB and iPSC models and primary AMLs, we performed
ChIP and ChIP-seq analysis, using an antibody recognizing both
RUNX1wt and RUNX1mut (Figure 6A; supplemental Figure 6A).
This revealed binding of RUNX1 in RUNX1mut-transduced
CB cells (CB-RUNX1mut) and in RUNX1mut-expressing iPSC
(iPSC-RUNX1mut) at similar sites as those in primary RUNX1mut
AMLs (Figure 6A). We found similar RUNX1 occupancy profiles
in control iPSCs, although with lower density (Figure 6A-B). We
identified 895 high-confidence RUNX1 binding sites shared among
CB-RUNX1mut, iPSC-RUNX1mut, and primary AMLs with a RUNX1
mutation (supplemental Figure 6B). Functional analysis of the genes
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associated with overlapping RUNX1 binding sites revealed enrich-
ment for processes associated with transcription and translation
(supplemental Figure 6C).
As RUNX1 binding has been associated with regulating the local
epigenetic environment, we investigated the epigenetic state
of the common RUNX1 binding sites by examining epigenetic
data of RUNX1mut AMLs.21 In line with the observation that most
of the common RUNX1mut binding sites are in promoters or
near genes (supplemental Figure 6D-E), our analysis revealed
enrichment for active chromatin marks such as DNaseI accessi-
bility, H3K4me3 and H3K27ac (supplemental Figure 6F), and
association of RUNX1 binding with genes that are actively
transcribed (supplemental Figure 6G). This is in accordance with the
reduced levels of repressive marks such as H3K27me3.
To determine whether this state is different in RUNX1wt AML cells,
we then compared the epigenetic state at RUNX1 binding sites
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common in RUNX1wt and RUNX1mut AMLs and the transcrip-
tional state of their target genes (supplemental Figure 6H). This
showed no global differences between RUNX1wt and RUN-
X1mut AMLs in the presence of active or repressive marks at
the common RUNX1 binding sites (supplemental Figure 6I),
suggesting the absence of a common epigenetic deregulating
mechanism by RUNX1mut. Interestingly, target gene expression
still varied significantly between RUNX1wt and RUNX1mut AMLs,
with approximately half the target genes upregulated and half the
target genes downregulated in RUNX1mut AML cells (Figure 6C,
middle). These alterations in gene activity at the local level did
correlate with epigenetic alterations, as exemplified for NUCB2
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(up in RUNX1wt) and TAL1 (up in RUNX1mut; Figure 6C, left
and right).
For a more general view, we zoomed into the genes that have
differential expression on RUNX1mut expression (Figure 5D,
clusters 3 and 4), and found that the levels of active chromatin
marks (mainly H3K27ac and H3K4me3) were higher in genes that
are upregulated compared with the genes that are downregulated
(supplemental Figure 6J). Levels of H3K27me3 were low overall, and
were not altered. For example, for CTSG, we found decreased
expression coinciding with less H3K27ac (Figure 6D), whereas
this was not observed for genes that are not differentially
expressed (supplemental Figure 6K). Expression of CEBPA
was also decreased, but not significantly, possibly because of
a limited number of studied AMLs. However, we did see a
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decrease in H3K27ac (Figure 6E), supporting our cell bi-
ological data.
These results suggest that RUNX1mut does not have a global
effect on the epigenetic state at its binding sites, but has specific
effects on genes important for granulocytic and monocytic
differentiation.
RUNX1mut and AML1-ETO have different
target genes
In view of the difference in clinical outcome between RUNX1mut
AMLs and AML-ETO AMLs, we investigated the difference in
oncogene binding. We identified 12 792 RUNX1mut and 4170
AML1-ETO peaks in our primary AMLs and found partial overlap
for RUNX1mut and AML1-ETO (supplemental Figure 7A). Sub-
sequently, we included recently published data on AML1-EVI1
binding.28 When comparing peak distributions from these data
sets, we found that RUNX1mut peaks are mostly located in promoters,
whereas AML1-ETO and AML1-EVI1 are intergenic, suggesting
distinct occupancy and regulatory roles resulting from the 3 types
of mutations (Figure 7A). Also, analysis of the genes in the direct
vicinity (15 kb, 21 kb; Figure 7B) identified only a small number
of direct AML1-ETO and AML1-EVI1 target genes. In this study,
we showed that in our iPSC model, RUNX1mut, similar as
shown for AML1-ETO (E.T., G.Y., Amit Mandoli, Jos G. A. Smits,
Francesco Ferrari, Falco Wijnen, Bowon Kim, Eva M. Janssen-
Megens, J.J.S., and J.H.A.M., manuscript in preparation; Mandoli
et al29; supplemental Figure 7B), is involved in repressing
granulocytic differentiation. However, when comparing specific
gene expression changes, we observed that key granulocytic
genes such as MPO and CTSG are more deregulated in
the RUNX1mut-expressing cells (Figure 7C; supplemental Figure
7C). Upregulated genes in RUNX1mut iPSCs, but not in
AML1-ETO iPSCs, include MEIS1, TCF4, ERG, and HMGA2,
genes previously described as being upregulated in leukemogen-
esis (supplemental Figure 7C; supplemental Table 3). Interest-
ingly, comparing RUNX1 binding differences in RUNX1mut and
AML1-ETO primary AMLs showed decreased binding of RUNX1
at many of these genes, including TCF4, HMGA2, and MN1, in
AML1-ETO AMLs (Figure 7D). In addition, we found that
RUNX1mut AMLs have decreased expression of granulocytic
genes such as CEBPE and ELANE (Figure 7E; supplemental
Table 4). Upregulated genes in RUNX1mut AMLs include genes
important for signal transduction and hematopoiesis, again
including TCF4, MN1, and MEIS1 (Figure 7E-F).
Finally, we were interested in whether we could rescue the
overexpression of these genes by CEBPA re-expression, as
we had conducted in our CB models. These results show thatMEIS1,
HMGA2, and CD34 were downregulated on overexpression of
CEBPA (supplemental Figure 7D), suggesting that CEBPA-mediated
differentiation might result in a decreased stem cell phenotype.
In conclusion, our results suggest that RUNX1mut occupies and
regulates different loci compared with AML1-ETO, and triggers
different gene expression patterns at a number of critical genes
relevant for granulocytic differentiation.
Discussion
To unravel the mechanisms by which RUNX1 mutations contribute
to leukemic transformation, we investigated the cell biological and
molecular consequences of a RUNX1 mutation as single genetic
hit in healthy CB-derived CD341 cells and in human iPSCs. The
resulting data were compared with those from RUNX1-mutated
and wild-type primary AML patient cells, and from patient samples
expressing the AML1-ETO fusion protein, which display rather
different molecular and clinical characteristics. This compari-
son showed that the RUNX1 truncation mutant S291fs300X
induces a differentiation block when introduced into CB CD341
cells or iPSCs. This results in the emergence of GMP-like cells,
which also express IL1-RAP, with increased self-renewal potential
in vitro.
The differentiation block at the GMP stage is linked to a reduced
expression of CEBPA in the myeloid lineage, which has been
described as a main deregulated gene in AML1-ETO.30 In our
study, re-expression of CEBPA partially rescued the differentia-
tion block, which is also in line with findings in AML1-ETO AMLs.31
RNA-seq analysis showed transcriptional differences regarding
the presence of the RUNX1mut in human in vitro models and
primary AMLs when compared with normal bone marrow CD341
cells, thereby identifying several clusters. PCA analysis of our
RNA-seq data revealed an enrichment of stem cell genes and
a loss of genes for granulocytic differentiation, reflecting the
differentiation block induced by the RUNX1mut. This suggests
that RUNX1mut dictates a distinct transcriptional program in
favor of transformation.
We analyzed model systems that have only 1 RUNX1 muta-
tion, thus excluding all secondary effects caused by addi-
tional mutations, and identified genes directly deregulated by
RUNX1mut. Our approach therefore has little overlap with a
recent study that compared RUNX1mut AMLs with RUNX1wt
AMLs.32 This is in line with the findings that RUNX1mut
requires additional mutations frequently found together with
RUNX1mut, including ASXL133 or elevated BMI1 expression,2
that epigenetically influence the expression of another set of
target genes.
By using ChIP-seq, we linked RUNX1mut binding to differ-
ences in histone modifications, revealing that RUNX1mut did
not completely reshape the localization of epigenetic marks.
The analysis showed that RUNX1mut can both induce and
repress target genes, and that this is associated with the amount
of activating histone modifications, mainly H3K27ac, suggesting
a more gene-specific regulation of transcription. This differs
from the activity of AML1-ETO, which has been shown to bind
mainly to introns and intergenic regions that are enriched in
accessible chromatin, marked with p300, but are generally low
in acetylation.34 Also, on direct gene binding, AML1-ETO leads
to gene repression, and thus has a dominant negative effect
relative to native AML1 by recruiting HDACs, NCoR, and
mSin3A.35-38
Transcriptional differences between RUNX1mut and AML1-ETO
in our iPSC models and primary AML cells include HMGA2,17
TCF4,39 and MEIS1.40 Previous studies have shown that the
expression of these genes is increased in AMLs, which makes them
potentially important targets of RUNX1mut, but not for AML1-ETO
in leukemogenesis.
In summary, the results of cellular assays, transcriptomic and epigenomic
profiling of human CB and iPSC models expressing RUNX1 mutations,
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demonstrate that RUNX1 binding and RNA expression recapitu-
late the effects of RUNX1-mutated primary AMLs. This indicates a
change in the RUNX1-dependent cellular programming that is
independent of additional mutations. This programming differs
between RUNX1mut and AML1-ETO-positive AMLs. This could
potentially explain the different clinical outcomes of patients with
AML harboring an RUNX1 mutation (poor risk) and those
harboring an AML1-ETO (good risk) translocation.
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